Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIx MDR-TB
NCT03568383Phase 3Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2019
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of delamanid in multidrug-resistant tuberculosis (MDR-TB), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2019; status: active, not recruiting.
02
Drugs
delamanid
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT03568383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03568383.